Angiogenesis in breast cancer: How should we measure this? (Review)

Oncology Reports

Volumn 13, Issue 5, 2005, Pages 931-936

  Pollitt, M J K ^a,b   Hanby, A M ^a   Horgan, K ^b   Murphy, C E ^a   Jones, P F ^a   Speirs, V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Angiogenesis; Breast cancer; VEGF

Indexed keywords

BREAST TUMOR; FEMALE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; REVIEW; VASCULARIZATION;

BREAST NEOPLASMS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 25144522798     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.5.931     Document Type: Review

References (68)

1. Folkman J: Tumour angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Ferrara N and Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851-858, 1989. (Pubitemid 19162712)
3. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
4. Weidner N, Folkman J, Pozza F, et al: Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84: 1875-1877, 1992.
5. Toi M, Bando H and Kuroi K: The predictive value of angiogenesis for adjuvant therapy in breast cancer. Breast Cancer 7: 311-314, 2000.
6. Toi M, Inada K, Susuki H and Tominga T: Tumour angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36: 195-202, 1995.
7. Eppenberger U, Kueng W, Schlaeppi JM, et al: Markers of tumour angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16: 3129-3136, 1998. (Pubitemid 28417436)
8. Gasparini G, Toi M, Gion M, et al: Prognostic significance of vascular endothelial growth factor in node-negative breast carcinoma. J Natl Cancer Inst 89: 139-147, 1997. (Pubitemid 27034790)
9. Linderholm B, Tavelin B, Grankvist K and Henriksson R: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16: 3121-3128, 1998. (Pubitemid 28417435)
10. De Paola F, Granato AM, Scarpi E, Monti F, et al: Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer. Int J Cancer 98: 228-233, 2002. (Pubitemid 34150807)
11. Robinson CJ and Stringer SE: The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853-865, 2001. (Pubitemid 32273121)
12. Xuri L and Eriksson U: Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int J Biochem Cell Biol 33: 421-426, 2001.
13. Lyttle DJ, Fraser KM, Fleming SB, Mercer AA and Robinson AJ: Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 68: 84-92, 1994.
14. Gunningham SP, Currie MJ, Han C, et al: VEGF-B expression in human primary breast cancer is associated with lymph node metastasis but not angiogenesis. J Pathol 193: 325-332, 2001. (Pubitemid 32229863)
15. Kinoshita J, Kitamura K, Kabashima A, et al: Clinical significance of vascular endothelial growth factor C (VEGF-C) in breast cancer. Breast Cancer Res Treat 66: 159-164, 2001. (Pubitemid 32521422)
16. Stacker SA, Stenvers K, Ceasar C, et al: Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem 274: 32127-32136, 1999.
17. Stacker SA, Caeser C, Baldwin ME, et al: VEGF-D promotes the metastatic spread of tumour cells via the lymphatics. Nat Med 7: 186-191, 2001. (Pubitemid 32148485)
18. Brem S, Cotran R and Folkman J: Tumour angiogenesis: a quantative method for histological grading. J Natl Cancer Inst 48: 347-356, 1972.
19. Weidner N, Semple JP, Welch WR and Folkman J: Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
20. Gasparini G and Harris AL: Clinical importance of the determination of tumour angiogenesis in breast carcinomas: much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
21. Heimann R, Ferguson D, Powers C, et al: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88: 1764-1769, 1996. (Pubitemid 26405014)
22. Takei H, Iino Y, Horiguchi J, et al: Highest microvessel count as a long-term prognostic factor in Japanese breast cancer patients. Cancer Lett 156: 109-116, 2000. (Pubitemid 30326774)
23. Toi M, Hoshina S, Takayanagi T and Tominaga T: Association of vascular endothelial growth factor expression with tumour angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85: 1045-1049, 1994. (Pubitemid 24325027)
24. Chalkley H: Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst 4: 47-53, 1943.
25. Fox SB, Leek RD, Weekes MP, et al: Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count and computer image analysis. J Pathol 177: 275-283, 1995.
26. Hansen S, Grabau DA, Rose C, et al: Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 78: 1563-1573, 1998. (Pubitemid 29022232)
27. Axelsson K, Ljung BM, Moore DH, Thor AD, et al: Tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87: 997-1008, 1995.
28. Fox SB, Gatter KC, Leek RD, et al: More about: tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 92: 161-162, 2000. (Pubitemid 30089874)
29. Fox SB: Tumour angiogenesis and prognosis. Histopathology 30: 294-301, 1997.
30. Hansen S, Grabau DA, Sorensen FB, et al: The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6: 139-146, 2000. (Pubitemid 30064986)
31. Kumar S, Ghellal A, Li C, et al: Breast carcinoma: vascular density determined using CD10 antibody correlates with tumour prognosis. Cancer Res 59: 856-861, 1999. (Pubitemid 29086739)
32. Wynendaele W, Derua R, Hoylaerts MF, et al: Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo. Ann Oncol 10: 965-971, 1999. (Pubitemid 29424578)
33. Van Trappen PO, Ryan A, Carroll M, et al: A model for coexpression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 87: 537-544, 2002.
34. Span PN, Grebenchtchikov N, Geurts-Moespot J, et al: EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumour tissue extracts. Int J Biol Markers 15: 184-191, 2000. (Pubitemid 30389368)
35. Webb NJA, Bottomley MJ, Watson CJ and Brenchley PEC: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 94: 395-404, 1998. (Pubitemid 28176624)
36. Banks RE, Forbes MA, Kinsey SE, et al: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurement and cancer biology. Br J Cancer 77: 956-964, 1998. (Pubitemid 28101786)
37. Vermeulen PB, Salvern P, Benoy I, et al: Blood platelets and serum VEGF in cancer patients. Br J Cancer 79: 370-373, 1999. (Pubitemid 29002310)
38. Gunsilis E, Petzer A, Stockerhammer G, et al: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58: 169-174, 2000. (Pubitemid 30113869)
39. Lee JK, Hong YJ, Han CJ, et al: Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimum specimen? Int J Oncol 17: 149-152, 2000.
40. Leek RD, Hunt NC, Lander RJ, et al: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190: 430-436, 2000. (Pubitemid 30163582)
41. Lewis JS, Landers RJ, Underwood JC, et al: Expression of vascular endothelial growth factor by macrophages is upregulated in poorly vascularised areas of breast carcinomas. J Pathol 192: 150-158, 2000.
42. Pinedo HM, Verheul HM, D'Amato RJ and Folkman J: Involvement of platelets in tumour angiogenesis. Lancet 352: 1775-1777, 1998.
43. Barbera-Guillem E, Nyhus JK, Wolford CC, et al: Vascular endothelial growth factor secretion by tumour-infiltrating macrophages essentially supports tumour angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62: 7042-7049, 2002. (Pubitemid 35424099)
44. O'Byrne KJ, Dobbs N, Propper D, et al: Vascular endothelial growth factor platelet counts and prognosis in renal cancer. Lancet 353: 1494-1495, 1999. (Pubitemid 29204372)
45. Dirix L, Salgado R, Weytjens R, et al: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 83: 389-396, 2002.
46. Salgado R, Vermeulen PB, Benoy I, et al: Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 80: 892-897, 1999. (Pubitemid 29209856)
47. Kendall RL and Thomas KA: Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90: 10705-10709, 1993. (Pubitemid 23347111)
48. Kumar H, Heer K, Greenman J, et al: Soluble FLT-1 is detected in the sera of colorectal and breast cancer patients. Anticancer Res 22: 1877-1880, 2002. (Pubitemid 34839213)
49. Hornig C, Behn T, Bartsch W, et al: Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J Immunol Methods 226: 169-177, 1999. (Pubitemid 29336541)
50. Toi M, Bando H, Ogawa T, et al: Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 98: 14-18, 2002. (Pubitemid 34113411)
51. Shima DT, Adamis AP, Ferrara N, et al: Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterisation of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1: 182-193, 1995.
52. Ferrara N and Bunting S: Vascular endothelial growth factor, a specifc regulator of angiogenesis. Curr Opin Nephrol Hypertens 5: 35-44, 1996. (Pubitemid 26088560)
53. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10-14, 2002.
54. Heer K, Kumar H, Speirs V, et al: Vascular endothelial growth factor in premenopausal women - indicator of the best time for breast cancer surgery? Br J Cancer 78: 1203-1207, 1998. (Pubitemid 28479152)
55. Agrawal R, Conway GS, Sladkevicius P, et al: Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: associations with changes in ovarian and uterine Doppler blood flow. Clin Endocrinol 50: 101-106, 1999. (Pubitemid 29079374)
56. McIlhenny C, George WD and Doughty JC: A comparison of serum and plasma levels of vascular endothelial growth factor during the menstrual cycle in healthy female volunteers. Br J Cancer 86: 1786-1789, 2002. (Pubitemid 34712924)
57. Linderholm B, Grankvist K, Wilkiling N, et al: Correlation of vascular endothelial growth factor content with recurrences, survival and first relapse in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18: 1423-1431, 2000. (Pubitemid 30205387)
58. Adams J, Carder PJ, Downey S, et al: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and the effects of tamoxifen. Cancer Res 60: 2898-2905, 2000. (Pubitemid 30395813)
59. Balsari A, Maier JA, Colnaghi MI and Menard S: Correlation between tumour vascularity, vascular endothelial growth factor production by tumour cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab Invest 79: 897-902, 1999. (Pubitemid 29344502)
60. Kristoffersen WM, Aspelin P, Perbeck L and Bone B: Value of MR imaging in the clinical evaluation of breast lesions. Acta Radiol 43: 275-281, 2002.
61. Tardivon AA, Guinebretiere JM, Dromain C and Vanel D: Imaging and management of non-palpable lesions of the breast. Eur J Radiol 42: 2-9, 2002. (Pubitemid 34232302)
62. Knopp MV, Weiss E, Sinn HP, et al: Pathophysiologic basis of contrast enhancement of breast tumours. J Magn Reson Imaging 10: 260-266, 1999. (Pubitemid 29463108)
63. Brasch R and Turetschek K: MRI characterization of tumours and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 34: 148-155, 2000. (Pubitemid 30601689)
64. Tatum JL and Hoffman JM: Role of imaging in clinical trials of antiangiogenesis therapy in oncology. Acad Radiol 7: 798-799, 2000.
65. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
66. Digby W and Keppler J: The current status of positron emission tomography. Radiol Management 22: 37-40, 2000.
67. Czernin J and Phelps ME: Positron emission tomography scanning: current and future applications. Ann Rev Med 53: 89-112, 2002. (Pubitemid 34177873)
68. (124)]-iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62: 5912-5919, 2002.